NYSE:MRKPharmaceuticals
Merck’s New HIV Drug And Mixed Oncology Data Reframe Growth Story
Merck (NYSE:MRK) received U.S. FDA approval for IDVYNSO, a new two drug, non INSTI, tenofovir free HIV regimen.
The company reported that a late stage trial of Welireg with Keytruda and Lenvima in first line kidney cancer did not meet its primary endpoints.
Separately, BioInvent announced strong interim data for its BI 1808 antibody combined with Merck's Keytruda in advanced ovarian cancer.
Merck enters this set of headlines with shares at $112.56 and a 47.7% return over the past year,...